Immune Checkpoint Inhibitors Market Regulations and
Competitive Landscape Outlook to 2027
April 2017
Report Id : REP-GB-3326
Status : Ongoing
Category : Healthcare, Pharmaceuticals & Medical Devices
©2015 Future Market Insights, All Rights Reserved
About
Future Market Insights
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom
research reports, and consulting services. We deliver a complete packaged solution, which
combines current market intelligence, statistical anecdotes, technology inputs, valuable growth
insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC,
ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy,
Technology, Healthcare, and Retail.
We have a global presence with delivery centers across India specializing in providing global
research reports and country research reports. FMI is headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning
from every corner of the world to distill it to one thing – the perfect solution for our client.
Research Capabilities




Customized
Research
Syndicated
Research
Investment
Research
Social Media
Research
Customized Research
Syndicated Research
Investment Research
Social Media Research
Sector Coverage




Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Subscription Information
For detailed subscription information please contact
Hari. T (Sr. Manager - Global Business Development)
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Email: [email protected]
©2015 Future Market Insights, All Rights Reserved
2
Research Methodology (1/2)
Systematic Research Approach
1
Market profiling
2
Formulating discussion guide
3
Developing list of respondents
4
In-depth secondary research is used to
ascertain overall market size, top
industry players, top products, industry
associations, etc.
PMR formulates a detailed discussion
guide to conduct expert and industry
interviews
PMR develops a list of industry players
(manufacturers), distributors, retailers
and industry experts
Data collection
PMR conducts interviews with industry
experts, industry players, distributors
and retailers
Data validation
Data is validated by triangulation
method, wherein secondary, primary
and PMR analysis contribute to the final
data
5
6
Data analysis
Insights
7
Data is scrutinized using MS-Excel to
obtain qualitative and quantitative
insights about the industry
PMR delivers industry insights and
information in the required format
(PDF)
Data
Collection




Research &
Intelligence
Data Filter
& Analysis
Identifying key opinion leaders
Questionnaire design
In-depth interviews
Coverage across value chain
Actionable
Insights
A
Primary
Research






B
SOLUTION





Market participants
Key strengths
Product portfolio
Mapping as per value chain
Key focus segments
Primary Research #




Linkedin
Zoominfo
Salesforce
Avention
Business
Solution
Desk
Research
C
Key industry experts
Channel study
Developments
Market dynamics
Products
Conclusions
Company
Analysis
Secondary Research #




Company websites
Company annual
reports
White papers
Financial reports
Paid Publications#




Factiva
GBI
Genios
Meltwater
# includes sources of databases
©2015 Future Market Insights, All Rights Reserved
3
Immune Checkpoint Inhibitors Market Regulations and Competitive
Landscape Outlook to 2027
Cancer is the leading cause of death worldwide and hence offers a lot of unmet research areas yet to be
targeted. The field of oncology is wide comprising a varied type of application area. The focus of
researchers is gradually shifting towards the immunotherapies. The immunotherapy makes the use of
body’s own components to fight cancer. Immune checkpoints are molecules that stimulate or inhibit the
immune cells. Yervoy was the first drug launched in the immune checkpoint inhibitors domain. This anitCTLA-4 drug was followed by many other drugs such as Keytruda and Opdivo. Besides these molecules
there are several others under clinical development. There is an ongoing competition between the
immune checkpoint inhibitors market contributors to emerge as a leader.
Immune Checkpoint Inhibitors Market: Drivers and Restraints
The immune checkpoint inhibitors market is driven by the number of research developments undertaken
by industry contributors as well as academic institutes. The immune checkpoint inhibitors market is
experiencing a lot of collaborations wherein companies are combining their core competencies to fasten
their research programs. For instance, Merck known as MSD outside the U.S. and Canada along with
Dynavax Technologies Corporation are investigating the potential synergistic effects by combining
Dynavax's SD-101 with two of Merck’s immunotherapies Keytruda and MK-1966.
©2015 Future Market Insights, All Rights Reserved
4
Immune Checkpoint Inhibitors Market Regulations and Competitive
Landscape Outlook to 2027
Immune Checkpoint Inhibitors Market: Overview
The immune checkpoint inhibitor market is driven by the need to address the rising rate of cancer
prevalence thereby affecting the country healthcare cost. In UK, lung cancer is the leading cause of
cancer related death. The survival rate past five years has only being 9% after the person is diagnosed
with lung cancer. The new form of immunotherapy based on the inhibition of programmed death-ligand 1
(PD-L1) and programmed death-1 (PD-1) receptors has shown hope as a therapy option for lung cancer.
Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3326
Immune Checkpoint Inhibitors Market: Region-wise Outlook
In terms of geography, immune checkpoint inhibitors market has been divided into five regions including
North- America, Asia- Pacific and Middle-East & Africa, Latin America and Europe. The number of clinical
trials and research funding is relatively high in North America, making it the dominant region in terms of
revenue in the immune checkpoint inhibitors market. In September 2014, Merck received accelerated
FDA approval for its Keytruda molecule to treat patient with advanced melanoma. The company is
forming global alliances with other companies to co-develop
©2015 Future Market Insights, All Rights Reserved
5
Immune Checkpoint Inhibitors Market Regulations and Competitive
Landscape Outlook to 2027
immnuo-oncology research and expand its oncology business.
Asia Pacific is the fastest growing region in the immune checkpoint inhibitors market as there are number
of research collaborations of international players with companies from this region. For instance, BristolMyers Squibb received Japanese approval for Opdivo in 2014, through partnership with Ono
Pharmaceuticals.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3326
Immune Checkpoint Inhibitors Market: Key Market Participants
Some of the market contributors to the immune checkpoint inhibitors market are Bristol-Myers
Squibb, Merck & Co., Inc., Roche, AstraZeneca, Merck KGaA, Ono Pharmaceutical Co., Ltd., Novartis
International AG, Juno Therapeutics and Kite Pharma.
©2015 Future Market Insights, All Rights Reserved
6
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
For media queries, contact the press office at
[email protected]
For other queries contact:
Harish Tiwari
(General Manager & Global Head Business Development)
Future Market Insights: 3rd Floor,
207 Regent Street, London W1B 3HH
T: +44 20 7692 8790 | D: +44 20 3287 4268
Email: [email protected]
Thank You
Future Market Insights Global & Consulting Private Limited (FMI)
©2015 Future Market Insights, All Rights Reserved
7